Open AccessPopulation-Based Sequencing of the V3-loop Can Predict the Virological Response to Maraviroc in Treatment-Naive Patients of the MERIT Trial
Author(s) -
Rachel A. McGovern,
Alexander Thielen,
Simon Portsmouth,
Theresa Mo,
Winnie Dong,
Conan K. Woods,
Xiaoyin Zhong,
Chanson J. Brumme,
Douglass Chapman,
Marilyn Lewis,
Ian James,
Jayvant Heera,
Hernán Valdez,
P. Richard Harrigan
Publication year - 2012
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0b013e31826249cf
Subject(s) - maraviroc , v3 loop , medicine , population , ccr5 receptor antagonist , oncology , virology , biology , human immunodeficiency virus (hiv) , immunology , inflammation , chemokine , environmental health , chemokine receptor , antigen , epitope
MERIT was a randomized trial comparing maraviroc (MVC) + Combivir versus efavirenz (EFV) + Combivir in drug-naive patients screened as having R5 HIV-1 by the original Trofile assay (OTA). We retrospectively evaluated treatment response after rescreening for viral tropism using population-based V3-loop sequencing.